ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
US Tech 100
18,488.00
-0.25%
Dow Jones
38,798.99
-0.22%
Brent Oil
79.675
0.42%
Bitcoin
69,663.21
0.01%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Evelo Biosciences Inc (EVLO)

  7. Evelo Biosciences Inc (EVLO) News

EVLO

Evelo Biosciences (EVLO)

Evelo Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EVLO
DateTimeSourceHeadlineSymbolCompany
01/26/20245:30PMEdgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:EVLOEvelo Biosciences Inc
01/26/20245:29PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
01/26/20245:28PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:EVLOEvelo Biosciences Inc
01/26/20245:27PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:EVLOEvelo Biosciences Inc
01/26/20245:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
12/12/20237:43AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:EVLOEvelo Biosciences Inc
12/12/20237:42AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
12/04/20236:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
12/01/20237:11AMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EVLOEvelo Biosciences Inc
11/21/20236:44AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
11/09/20235:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
11/08/20238:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
11/08/20238:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
11/08/20238:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
11/03/20234:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
11/03/20234:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
11/03/20234:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
10/27/20235:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
10/17/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
10/17/20237:00AMGlobeNewswire Inc.Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisNASDAQ:EVLOEvelo Biosciences Inc
09/13/20238:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
09/13/20238:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
09/13/20238:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EVLOEvelo Biosciences Inc
08/21/20235:25PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
08/21/20235:25PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EVLOEvelo Biosciences Inc
08/21/20237:43AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
08/18/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVLOEvelo Biosciences Inc
08/14/20238:14AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVLOEvelo Biosciences Inc
08/14/20237:42AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVLOEvelo Biosciences Inc
08/14/20237:30AMGlobeNewswire Inc.Evelo Biosciences Announces Second Quarter Financial Results and Recent Business HighlightsNASDAQ:EVLOEvelo Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:EVLO

Your Recent History

BIT
P1HLG0
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved